AMG-529 is a humanized monoclonal antibody against ASGR1 that binds to ASGR1, blocks ligand binding, and causes a dose-dependent increase in ALP (a biomarker of ASGR1 inhibition). AMG-529 can be used for the research of cardiovascular diseases [1].
In Vitro, AMG-529 induces a dose-dependent increase in alkaline phosphatase (ALP) levels, but no significant effect on blood lipid levels (including non-high-density lipoprotein cholesterol) is observed[1].
References:
[1]. Janiszewski M, et al. A randomized, placebo-controlled, double-blind, ascending single-dose, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 529, a novel anti-ASGR1 monoclonal antibody, in healthy subjects. Journal of the American College of Cardiology. 2019 Mar 12;73(9S1):1755-.
In Vitro, AMG-529 induces a dose-dependent increase in alkaline phosphatase (ALP) levels, but no significant effect on blood lipid levels (including non-high-density lipoprotein cholesterol) is observed[1].
References:
[1]. Janiszewski M, et al. A randomized, placebo-controlled, double-blind, ascending single-dose, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 529, a novel anti-ASGR1 monoclonal antibody, in healthy subjects. Journal of the American College of Cardiology. 2019 Mar 12;73(9S1):1755-.